JP6211767B2 - ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 - Google Patents

ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 Download PDF

Info

Publication number
JP6211767B2
JP6211767B2 JP2012528909A JP2012528909A JP6211767B2 JP 6211767 B2 JP6211767 B2 JP 6211767B2 JP 2012528909 A JP2012528909 A JP 2012528909A JP 2012528909 A JP2012528909 A JP 2012528909A JP 6211767 B2 JP6211767 B2 JP 6211767B2
Authority
JP
Japan
Prior art keywords
actriib
amino acid
fusion protein
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012528909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504589A5 (enExample
JP2013504589A (ja
Inventor
ジャスバー シーラ，
ジャスバー シーラ，
ジョン ノフ，
ジョン ノフ，
ケン アティー，
ケン アティー，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド, アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2013504589A publication Critical patent/JP2013504589A/ja
Publication of JP2013504589A5 publication Critical patent/JP2013504589A5/ja
Application granted granted Critical
Publication of JP6211767B2 publication Critical patent/JP6211767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012528909A 2009-09-09 2010-09-09 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 Active JP6211767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27628709P 2009-09-09 2009-09-09
US61/276,287 2009-09-09
PCT/US2010/048322 WO2011031901A1 (en) 2009-09-09 2010-09-09 Actriib antagonists and dosing and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015027521A Division JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Publications (3)

Publication Number Publication Date
JP2013504589A JP2013504589A (ja) 2013-02-07
JP2013504589A5 JP2013504589A5 (enExample) 2013-10-24
JP6211767B2 true JP6211767B2 (ja) 2017-10-11

Family

ID=43732801

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012528909A Active JP6211767B2 (ja) 2009-09-09 2010-09-09 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2015027521A Withdrawn JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2016232363A Withdrawn JP2017048243A (ja) 2009-09-09 2016-11-30 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2017193336A Withdrawn JP2018002730A (ja) 2009-09-09 2017-10-03 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2018227174A Withdrawn JP2019055977A (ja) 2009-09-09 2018-12-04 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2020105837A Pending JP2020146070A (ja) 2009-09-09 2020-06-19 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015027521A Withdrawn JP2015108012A (ja) 2009-09-09 2015-02-16 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2016232363A Withdrawn JP2017048243A (ja) 2009-09-09 2016-11-30 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2017193336A Withdrawn JP2018002730A (ja) 2009-09-09 2017-10-03 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2018227174A Withdrawn JP2019055977A (ja) 2009-09-09 2018-12-04 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2020105837A Pending JP2020146070A (ja) 2009-09-09 2020-06-19 ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用

Country Status (13)

Country Link
US (3) US20110070233A1 (enExample)
EP (3) EP2475427B1 (enExample)
JP (6) JP6211767B2 (enExample)
KR (4) KR20200086378A (enExample)
CN (1) CN102781518A (enExample)
AU (4) AU2010292203A1 (enExample)
BR (1) BR112012005225B8 (enExample)
CA (1) CA2773494A1 (enExample)
ES (2) ES2613523T3 (enExample)
IL (1) IL218502A0 (enExample)
IN (1) IN2012DN02766A (enExample)
MX (2) MX385217B (enExample)
WO (1) WO2011031901A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
WO2008100384A2 (en) 2007-02-09 2008-08-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CA2749544A1 (en) * 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN104805105A (zh) 2009-06-12 2015-07-29 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
ES2869864T3 (es) * 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
EP2948161B1 (en) * 2013-01-25 2018-12-12 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US20140220033A1 (en) * 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
LT3227675T (lt) 2014-12-03 2023-06-12 Celgene Corporation Aktivino actrii antagonistai ir naudojimas mielodisplastiniam sindromui gydyti
AU2016238254B2 (en) 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
RU2733492C2 (ru) 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
JP6976859B2 (ja) * 2015-05-13 2021-12-08 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
CN109311998A (zh) * 2016-02-22 2019-02-05 阿塞勒隆制药公司 用于增加免疫活性的ActRII拮抗剂
AU2017230091B2 (en) 2016-03-10 2022-04-07 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US11185569B2 (en) * 2016-05-04 2021-11-30 University Of Cincinnati ActRIIB:Fc to treat infertility in females
KR102595559B1 (ko) 2016-10-05 2023-10-30 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN110461349B (zh) 2016-11-10 2024-08-13 科乐斯疗法公司 激活素受体iia型变体及其使用方法
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3087008A1 (en) 2018-01-12 2019-07-18 Keros Therapeutics, Inc. Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
AU2021270458A1 (en) 2020-05-13 2022-11-10 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
AU2021377176A1 (en) * 2020-11-11 2023-06-22 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP1475440A3 (en) * 1993-01-12 2004-11-17 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) * 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US6132988A (en) * 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6440930B1 (en) * 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) * 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US6632180B1 (en) * 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
DE60236861D1 (de) 2001-04-26 2010-08-12 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
AU2002256388A1 (en) 2001-04-30 2002-11-11 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
IL163525A0 (en) * 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
AU2003232485A1 (en) * 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) * 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2004086953A2 (en) * 2003-03-26 2004-10-14 The Board Of Trustees Of The University Of Arkansas Method for diagnosis and treatment of bone turnover
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
UA85055C2 (ru) * 2003-06-02 2008-12-25 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
AU2005307789A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
CA3045808C (en) * 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7361510B2 (en) * 2006-01-20 2008-04-22 Beckman Coulter, Inc. Methods of detection of iron deficiency
CA2650131A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
CA2652235A1 (en) * 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
MX2009000722A (es) * 2006-07-21 2009-06-11 Lyne Lab Composiciones liquidas de acetato de calcio.
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX373050B (es) * 2006-12-18 2020-05-21 Acceleron Pharma Inc Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojos.
RU2473362C2 (ru) * 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
WO2008100384A2 (en) * 2007-02-09 2008-08-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
JP2010529041A (ja) * 2007-06-01 2010-08-26 ワイス・エルエルシー Ｂｍｐ−１０活性を調整する方法および組成物
CN101861161B (zh) * 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201919685A (zh) * 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CA2749544A1 (en) * 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP3275900A1 (en) * 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
CA2764890A1 (en) * 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN104805105A (zh) * 2009-06-12 2015-07-29 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
ES2869864T3 (es) * 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
EP2501400B1 (en) * 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EA202090053A3 (ru) * 2011-10-17 2020-06-30 Акселерон Фарма, Инк. Способы и композиции для лечения неэффективного эритропоэза
ES2720401T3 (es) * 2012-07-02 2019-07-22 Kyowa Hakko Kirin Co Ltd Agente terapéutico para la anemia que incluye la anemia renal y la anemia inducida por cáncer que contiene anticuerpo anti-BMP9 como principio activo

Also Published As

Publication number Publication date
US20210115105A1 (en) 2021-04-22
MX385217B (es) 2025-03-14
JP2019055977A (ja) 2019-04-11
BR112012005225B8 (pt) 2023-01-10
EP3919068A1 (en) 2021-12-08
US20110070233A1 (en) 2011-03-24
AU2020204176A1 (en) 2020-07-09
AU2018200463B2 (en) 2020-07-09
EP3202459A1 (en) 2017-08-09
AU2016201712B2 (en) 2017-10-26
ES2869580T3 (es) 2021-10-25
KR20190047117A (ko) 2019-05-07
KR20210029836A (ko) 2021-03-16
EP2475427A4 (en) 2013-06-26
MX340451B (es) 2016-07-08
JP2018002730A (ja) 2018-01-11
CN102781518A (zh) 2012-11-14
JP2013504589A (ja) 2013-02-07
WO2011031901A1 (en) 2011-03-17
US20180194828A1 (en) 2018-07-12
AU2018200463A1 (en) 2018-02-08
KR102133683B1 (ko) 2020-07-14
EP2475427A1 (en) 2012-07-18
JP2020146070A (ja) 2020-09-17
BR112012005225A2 (pt) 2020-09-01
EP3202459B1 (en) 2021-04-14
ES2613523T3 (es) 2017-05-24
IN2012DN02766A (enExample) 2015-09-18
CA2773494A1 (en) 2011-03-17
JP2015108012A (ja) 2015-06-11
KR20200086378A (ko) 2020-07-16
AU2010292203A1 (en) 2012-04-12
MX2012003005A (es) 2012-06-12
IL218502A0 (en) 2012-07-31
EP2475427B1 (en) 2016-11-30
JP2017048243A (ja) 2017-03-09
AU2016201712A1 (en) 2016-04-07
BR112012005225B1 (pt) 2022-04-19
KR20120062874A (ko) 2012-06-14
MX2019006655A (es) 2019-09-09

Similar Documents

Publication Publication Date Title
JP6211767B2 (ja) ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP6662939B2 (ja) ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
JP6195885B2 (ja) アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
JP6132861B2 (ja) 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
JP2009517051A5 (enExample)
HK40036911A (en) Variants derived from actriib and uses thereof
HK1227889A1 (en) Variants derived from actriib and uses therefor
HK1228413B (zh) 由actriib衍生的变体及其用途
HK1228411B (zh) 由actriib衍生的变体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170914

R150 Certificate of patent or registration of utility model

Ref document number: 6211767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250